knowledge -WSS

knowledge

author：knowledge 2025-09-06 03:26:01 - browse：596

light shines behind Pfizer CEO Albert Bourla as he attends a ceremony in Greece — Pfizer CEO Albert Bourla Giannis Papanikos/AP

Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer are the solution.

Shares in the drugmaker fell 44% last year, and it now has a market capitalization of only $150 billion — a quarter that of Eli Lilly and half that of longtime rival Merck. In March of last year the company announced that it would spend $43 billion to buy Seagen, a maker of a hot category of oncology medicines called antibody-drug conjugates. Pfizer’s shares have slumped another 9% so far this year. On Thursday, executives are holding an investor briefing to try to convince shareholders that its bet will pay off.

In an interview with STAT, Pfizer CEO Albert Bourla was insistent that the deal’s potential is being missed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： FDA seeking to stop procedures at two unregulated stem cell clinics

WSS

DeSantis says Trump could've 'come out more forcefully' during Jan. 6

Neuroscience renaissance leads to new crop of psychiatric drugs

Study fuels hope CAR

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

Using force crossed my mind when examining a defiant young patient

'Vaccine

knowledge

knowledge

explore

United colonoscopy coverage change 'may cost lives,' doctors say

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Redefining sustainability for the pharmaceutical industry

State Dept. review finds Biden bears some blame for Afghanistan failures

CDC advisory group OKs chikungunya vaccine

State Dept. review finds Biden bears some blame for Afghanistan failures

Study fuels hope CAR

hotspot

Vivek Ramaswamy, who's embraced Trump on the campaign trail, condemned him after Jan. 6

Medicare isn't yet testing food as medicine

Change Healthcare cyberattack shows risk of industry consolidation

A Theranos scientist

FDA seeking to stop procedures at two unregulated stem cell clinics

CDC panel: People 65 and older should get a Covid spring booster shot

focus

leisure time

entertainment

knowledge